

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Immunotech Biopharm Ltd**

**永泰生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6978)**

**PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND  
ARTICLES OF ASSOCIATION AND ADOPTION OF  
THE THIRD MEMORANDUM AND ARTICLES OF ASSOCIATION**

This announcement is issued by Immunotech Biopharm Ltd (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(1) of the Rules (the “**Listing Rules**”) Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company proposed to (i) make certain amendments (the “**Proposed Amendments**”) to the second amended and restated memorandum of association and articles of association of the Company (the “**Existing Memorandum and Articles of Association**”), for the purpose of, among others, conforming to the core shareholder protection standards set out in Appendix 3 to the Listing Rules; and (ii) adopt the third amended and restated memorandum of association and articles of association of the Company incorporating and consolidating all the Proposed Amendments (the “**Third Amended and Restated Memorandum and Articles of Association**”) for the purposes of, among others, (i) bringing the Third Amended and Restated Memorandum and Articles of Association in line with amendments made to Listing Rules and applicable laws and procedures of the Cayman Islands; and (ii) making certain minor housekeeping amendments to the Existing Memorandum and Articles of Association.

The Proposed Amendments and the adoption of the Third Amended and Restated Memorandum and Articles of Association are subject to the approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming annual general meeting (the “**AGM**”) of the Company, and will become effective upon the approval by the Shareholders at the AGM. A circular of the Company containing detailed information of the Proposed Amendments as well as the adoption of the Third Amended and Restated Memorandum and Articles of Association together with a notice convening the AGM will be dispatched to the Shareholders in due course.

By order of the Board  
**Immunotech Biopharm Ltd**  
**Tan Zheng**  
*Chairman and executive Director*

Hong Kong, 24 March 2023

*As at the date of this announcement, the Board comprises Mr Tan Zheng as Chairman and executive Director, Dr Wang Yu and Mr Jung Hyun Chul as executive Directors, Mr Tao Ran, Mr Si Xiaobing and Mr Lu Yuan as non-executive Directors, and Professor Wang Yingdian, Mr Ng Chi Kit and Ms Peng Sujiu as independent non-executive Directors.*